|
|
|
Volumn , Issue AUTUMN, 2005, Pages 8-10
|
|
The pendulum swings towards M&As and partnering for biotechs
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AD 237;
ANA 975;
ANIDULAFUNGIN;
ANTINEOPLASTIC AGENT;
ANTIVIRUS AGENT;
BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT;
CEFTOBIPROLE;
CEPHALOSPORIN DERIVATIVE;
CPG 7909;
DALBAVANCIN;
DORIPENEM;
FLUCONAZOLE;
INDACATEROL;
LEVOFLOXACIN;
LISDEXAMFETAMINE;
MUSCARINIC AGENT;
NEUROLEPTIC AGENT;
OLIGONUCLEOTIDE;
PEGAPTANIB;
PRODRUG;
TOLL LIKE RECEPTOR 9;
UNCLASSIFIED DRUG;
ARTICLE;
ATTENTION DEFICIT DISORDER;
BIOTECHNOLOGY;
CAPITAL;
CLINICAL TRIAL;
DRUG APPROVAL;
DRUG DOSE REGIMEN;
DRUG INDUSTRY;
DRUG MANUFACTURE;
DRUG MARKETING;
DRUG RESEARCH;
ECONOMIC EVALUATION;
FINANCIAL MANAGEMENT;
FOOD AND DRUG ADMINISTRATION;
GRAM NEGATIVE INFECTION;
HEPATITIS;
HUMAN;
INVESTMENT;
MALIGNANT NEOPLASTIC DISEASE;
MYCOSIS;
PATENT;
|
|
EID: 26844458713
PISSN: 1364369X
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (1)
|
|
References (0)
|
